HEPA Hepion Pharmaceuticals, Inc.
USHealthcareAs of 2026-07-10 16:00
Why HEPA matters now
Hepion Pharmaceuticals, Inc. (HEPA) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.06 with -14.29% on the session and $698.6K in market capitalization; recent performance reads 1-month -16.20% and YTD +0.00%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-810.8K, and EPS of $-0.07. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -225.5%.
Additional event context on this page matters because analyst consensus is Buy with a median target of $70.00; recent insider activity includes LoPriore Chase filing . These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.38
P/S
0.00
EV/EBITDA
0.64
DCF Value
$0.17
FCF Yield
-225.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-102.5%
ROA
-110.2%
ROIC
-186.9%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-810.8K | $-0.07 |
| Q4 2025 | $0.00 | $-656.9K | $-0.06 |
| FY 2025 | $0.00 | $-8.3M | $-0.88 |
| Q3 2025 | $0.00 | $-472.5K | $-0.04 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$70.00
Target (Median)
$70.00
Target Range
$70.00 - $70.00
Trading Activity
Insider Trades
Related Stocks
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.66
Hepion Pharmaceuticals, Inc., a U.S.-based biopharmaceutical entity, is dedicated to developing therapeutic interventions for chronic hepatic ailments. Central to their efforts is Rencofilstat, a cyclophilin inhibitor that has successfully concluded Phase 2a clinical trials. This compound operates by disrupting multiple pathological pathways implicated in the worsening of liver disease. It is currently progressing through clinical development for non-alcoholic steatohepatitis (NASH) and is additionally being explored in nonclinical research for its potential to reduce liver fibrosis and lessen hepatocellular carcinoma tumor loads in experimental models of NASH. Moreover, Rencofilstat has exhibited antiviral properties against hepatitis B, C, and D viruses through diverse mechanisms. The company, established in 2013 and situated in Edison, New Jersey, rebranded as Hepion Pharmaceuticals, Inc. in July 2019, having previously operated as ContraVir Pharmaceuticals, Inc.